Neurorehabilitation News

CHICAGO — Researchers have reported a link between a novel DCTN1 variant and Perry syndrome, which was identified both in asymptomatic individuals and those with mild neurological abnormalities, suggesting a prodromal stage of disease.

CHICAGO – The Huntington Disease Health Index was an accurate, clinically meaningful tool for participants in the KINECT-HD trial to report symptomatic disease burden changes when treated with valbenazine, according to a recent study.

Access to early amyloid position emission tomography allowed those with memory issues to receive a diagnosis with very high confidence at 3 months compared with those who did not undergo PET, according to research in JAMA Neurology.

The FDA has approved expanded MRI labeling for Abbott’s Eterna spinal cord stimulation system, allowing those with chronic pain to undergo MRI within specific conditions and have a wider selection of lead options for full-body scans.

The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

Physical wellness and social functioning were adversely affected in adults who were aware of abnormal involuntary movements indicative of tardive dyskinesia, according to research in the Journal of Patient-Reported Outcomes.

The FDA has granted 510(k) clearance to Cumulus Neuroscience for its dry-sensor electroencephalogram headset, for self-directed use by adolescents and adults at home or at health care facilities.

BOSTON — Treatment with Leqembi reduced markers of amyloid and tau in patients with early Alzheimer’s disease and slowed cognitive and functional decline at 18 months, according to data at the American Academy of Neurology annual meeting.

BOSTON — Long-term treatment with Vyvgart was safe, well-tolerated and effective in reducing immunoglobulin G antibody levels and improving clinical outcomes in patients with generalized myasthenia gravis.